SPL 2.11% 9.3¢ starpharma holdings limited

Ann: US patent issued for DEP cabazitaxel nanoparticle, page-21

  1. 2,065 Posts.
    lightbulb Created with Sketch. 304
    Management have been spruiking about the viral conjunctivitis drops and "commercial discussions" since 2014.

    A patent was granted in 2018.

    Before anything else clinical trials need to be conducted which to me as a layman should be relatively straight forward.

    So can someone please tell me why nothing has eventuated and please don't blame Covid-19

    Here we have no approved therapies and an estimated market of AU $1billion annually

    This question is a must for the AGM.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.